March 19, 2024

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Supported by GlaxoSmithKline and Novartis. Dr. Larkin is supported by the National Institute for Health Research Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research.

Dr. Long is supported by an Australian National Health and Medical Research Council fellowship and the University of Sydney Medical Foundation.

Disclosure forms provided by the authors are available with the full text of this article at NEJM. org.

Dr. Long reports receiving consulting fees from Amgen, Array BioPharma, Bristol-Myers Squibb, Merck Sharp Dohme, Novartis, Pierre Fabre, and Roche; Dr. Hauschild, receiving grant support, lecture fees, and consulting fees from Amgen, Bristol-Myers Squibb, Merck, Pierre Fabre, Provectus, and Roche, grant support and consulting fees from Merck Serono, Philogen, and Regeneron, and consulting fees from OncoSec;

Dr. Atkinson, receiving travel support, advisory board fees, and lecture fees from Merck Sharp Dohme, Bristol-Myers Squibb, and Novartis, lecture fees from Roche, and advisory board fees from Pierre Fabre; Dr. Mandalà, receiving grant support, advisory board fees, and lecture fees from Roche and advisory board fees and lecture fees from Novartis, Merck Sharp Dohme, and Bristol-Myers Squibb; Dr. Chiarion-Sileni, receiving advisory board fees from Bristol-Myers Squibb, Merck Sharp Dohme, Roche, Novartis, and Merck Serono;

Dr. Larkin, receiving grant support, paid to his institution, and consulting fees from Bristol-Myers Squibb, Merck Sharp Dohme, Pfizer, and Novartis and consulting fees from Eisai, GlaxoSmithKline, Kymab, Roche/Genentech, Secarna, Pierre Fabre, and EUSA Pharma; Dr. Mortier, receiving fees for serving on a medical board from Roche; Dr. Schadendorf, receiving grant support, consulting fees, lecture fees, and fees for serving on speakers bureaus from Novartis and Bristol-Myers Squibb, consulting fees, lecture fees, and fees for serving on speakers bureaus from Merck, Amgen, and GlaxoSmithKline, and consulting fees from Sysmex and Boehringer Ingelheim;

Dr. Lesimple, receiving advisory board fees from Novartis, advisory board fees, travel support, and drugs from Roche, and advisory board fees and travel support from Merck Sharp Dohme; Dr. Plummer, receiving clinical trial support, paid to her institution, and consulting fees from Novartis/GlaxoSmithKline; Dr. Ji, being employed by Novartis; Dr. Zhang, being employed by Novartis; Dr. Mookerjee, being employed by and having stock options in Novartis and GlaxoSmithKline; Dr. Legos, being employed by and being a shareholder in Novartis;

Dr. Kefford, receiving advisory board fees and fees for conference reporting, paid to his institution, from Bristol-Myers Squibb, and advisory board fees, paid to his institution, from Merck, Amgen, and Teva; Dr. Dummer, receiving consulting fees from Novartis, Merck Sharp Dohme, Roche, Takeda, and Pierre Fabre and grant support and consulting fees from Bristol-Myers Squibb and Amgen; and Dr. Kirkwood, receiving grant support, paid to his institution, from Merck and Prometheus and advisory board fees from Bristol-Myers Squibb, Novartis, Roche, Genentech, EMD Serono, and Array BioPharma. No other potential conflict of interest relevant to this article was reported.

Leave a Reply

Your email address will not be published. Required fields are marked *